Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net revenue | $796,197 | $724,508 | $1,518,716 | $1,419,928 |
| Cost of goods sold | 461,689 | 438,255 | 864,095 | 877,784 |
| Gross profit | 334,508 | 286,253 | 654,621 | 542,144 |
| Selling, general and administrative | 148,722 | 124,266 | 287,582 | 242,554 |
| Research and development | 39,017 | 47,964 | 77,400 | 88,004 |
| Intellectual property legal development expenses | 2,087 | 2,017 | 3,629 | 3,784 |
| Acquisition costs | 7,600 | — | 12,753 | — |
| Restructuring and other charges | 554 | 1,024 | 1,204 | 1,595 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s SG&A?
- Amneal Pharmaceuticals, Inc. (AMRX) reported SG&A of $148.72M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s SG&A changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s SG&A increased by 19.7% year-over-year, from $124.27M to $148.72M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s SG&A?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s SG&A has grown at a 9.6% compound annual growth rate (CAGR), from $365.5M to $526.83M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Amneal Pharmaceuticals, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude